Inhibition of the epigenetic suppressor EZH2 primes osteogenic differentiation mediated by BMP2
Amel Dudakovic, Rebekah M. Samsonraj, Christopher R. Paradise, Catalina Galeano‐Garces, Merel O. Mol, Daniela Galeano, Pengfei Zan, M. Lizeth Galvan, Mario Hevesi, Oksana Pichurin, Roman Thaler, Dana L. Begun, Peter Kloen, Marcel Karperien, A. Noelle Larson, Jennifer J. Westendorf, Simon M. Cool, André J. van Wijnen
Abstract
Osterix/SP7 and IBSP). A combination of BMP2 (300 ng local) and GSK126 (5 μg local and 5 days of 50 mg/kg systemic) yielded more consistent bone healing than single treatments with either compound in a mouse calvarial critical-sized defect model according to results from μCT, histomorphometry, and surgical grading of qualitative X-rays. We conclude that EZH2 inhibition facilitates BMP2-mediated induction of osteogenic differentiation of progenitor cells and maturation of committed osteoblasts. We propose that epigenetic priming, coupled with bone anabolic agents, enhances osteogenesis and could be leveraged in therapeutic strategies to improve bone mass.